STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today…
ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES
Share this article
More News


VTI is up 0.4% today, on MRVL stock price movement
August 20, 2026

Trump urges Congress to pass the Clarity Act
August 20, 2026

Technical Analysis on One ASX-Listed Materials Stock – G50
August 20, 2026

Lyft Stock Analysis: Value Stock or Value Trap?
August 20, 2026